YIFAN PHARMACEUTICAL CO (SZSE:002019) Short-Term Debt & Capital Lease Obligation : ¥1,236 Mil (As of Mar. 2024)

View and export this data going back to 2004. Start your Free Trial

What is YIFAN PHARMACEUTICAL CO Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. YIFAN PHARMACEUTICAL CO's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥1,236 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. YIFAN PHARMACEUTICAL CO's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥777 Mil.

YIFAN PHARMACEUTICAL CO Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for YIFAN PHARMACEUTICAL CO's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

YIFAN PHARMACEUTICAL CO Short-Term Debt & Capital Lease Obligation Chart

YIFAN PHARMACEUTICAL CO Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

1,826.76

1,221.77

1,438.89

1,231.24

1,101.72

YIFAN PHARMACEUTICAL CO Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															1,240.84	1,156.72	1,124.59	1,101.72	1,235.67

YIFAN PHARMACEUTICAL CO Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

YIFAN PHARMACEUTICAL CO Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of YIFAN PHARMACEUTICAL CO's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

YIFAN PHARMACEUTICAL CO (SZSE:002019) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » YIFAN PHARMACEUTICAL CO LTD (SZSE:002019) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 50 Qinshan, Jincheng, Lin'an Economic Development Zone, Hangzhou, Zhejiang, CHN, 311300

Website

https://en.yifanyy.com

YIFAN PHARMACEUTICAL CO LTD is a China-based company engaged in pharmaceutical innovation and manufacturing. The company focuses its activities on key areas like macromolecular biologics, high-value pharmaceuticals, and differentiated traditional Chinese medicines. The products of the company are F-627 for Neutropenia and Parkinson's disease, F-652 for acute alcoholic hepatitis, GvHD and acute pancreatitis and F-899 for growth deficiency. The company's products are sold in China and internationally.

Executives

Ye Yi Qun	Director
Zhang Da Wei	Executives
Geng Yu Hong	Executives
Feng De Qi	Directors, Directors, and Executives
Zhou Ben Yu	Director
Lin Xing	Directors, executives
Yu Hai Xia	Executives
Cheng Xian Feng	Directors, executives
Xu Guo Han	Supervisors
Cao Shi Mei	Director
Lin Guan Yu	Director
Zhang Lian Chun	Executives
Guo Xin Fu	Director
Zheng Shi Ming	Supervisors
Yin Hang Hua	Executives

YIFAN PHARMACEUTICAL CO (SZSE:002019) Headlines

No Headlines